NASDAQ:EXEL

Exelixis (EXEL) Stock Price, News & Analysis

$23.71
+0.42 (+1.80%)
(As of 04/24/2024 ET)
Today's Range
$23.19
$23.78
50-Day Range
$20.48
$23.92
52-Week Range
$18.08
$24.34
Volume
1.63 million shs
Average Volume
2.28 million shs
Market Capitalization
$6.99 billion
P/E Ratio
37.05
Dividend Yield
N/A
Price Target
$26.29

Exelixis MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
10.9% Upside
$26.29 Price Target
Short Interest
Healthy
2.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.63
Upright™ Environmental Score
News Sentiment
0.33mentions of Exelixis in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$3.93 M Bought Last Quarter
Proj. Earnings Growth
25.62%
From $1.21 to $1.52 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.98 out of 5 stars

Medical Sector

5th out of 909 stocks

Biological Products, Except Diagnostic Industry

2nd out of 156 stocks

EXEL stock logo

About Exelixis Stock (NASDAQ:EXEL)

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

EXEL Stock Price History

EXEL Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
What Analysts Are Saying About Exelixis Stock
3 Biotech Gems Poised for April Breakthroughs
10 Mid-Cap Stocks with Insider Purchases
Stock Offerings Prompt Big Insider Buying
Truist Financial Keeps Their Buy Rating on Exelixis (EXEL)
See More Headlines
Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/06/2024
Today
4/24/2024
Next Earnings (Confirmed)
4/30/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:EXEL
CUSIP
30161Q10
Employees
1,310
Year Founded
1994

Price Target and Rating

Average Stock Price Target
$26.29
High Stock Price Target
$32.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+10.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
15 Analysts

Profitability

Net Income
$207.76 million
Pretax Margin
14.07%

Debt

Sales & Book Value

Annual Sales
$1.83 billion
Cash Flow
$0.80 per share
Book Value
$7.47 per share

Miscellaneous

Free Float
286,251,000
Market Cap
$6.99 billion
Optionable
Optionable
Beta
0.54

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives


EXEL Stock Analysis - Frequently Asked Questions

Should I buy or sell Exelixis stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EXEL shares.
View EXEL analyst ratings
or view top-rated stocks.

What is Exelixis' stock price target for 2024?

15 Wall Street analysts have issued 12-month price targets for Exelixis' shares. Their EXEL share price targets range from $18.00 to $32.00. On average, they expect the company's share price to reach $26.29 in the next year. This suggests a possible upside of 10.9% from the stock's current price.
View analysts price targets for EXEL
or view top-rated stocks among Wall Street analysts.

How have EXEL shares performed in 2024?

Exelixis' stock was trading at $23.99 at the beginning of 2024. Since then, EXEL stock has decreased by 1.2% and is now trading at $23.71.
View the best growth stocks for 2024 here
.

Are investors shorting Exelixis?

Exelixis saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 6,830,000 shares, a drop of 17.2% from the March 15th total of 8,250,000 shares. Based on an average daily trading volume, of 2,340,000 shares, the short-interest ratio is currently 2.9 days. Currently, 2.3% of the shares of the stock are sold short.
View Exelixis' Short Interest
.

When is Exelixis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our EXEL earnings forecast
.

How can I listen to Exelixis' earnings call?

Exelixis will be holding an earnings conference call on Tuesday, April 30th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) released its quarterly earnings results on Tuesday, February, 6th. The biotechnology company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.25 by $0.02. The biotechnology company had revenue of $479.65 million for the quarter, compared to analyst estimates of $481.23 million. Exelixis had a net margin of 11.35% and a trailing twelve-month return on equity of 8.57%.

What guidance has Exelixis issued on next quarter's earnings?

Exelixis updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.8 billion-$1.9 billion, compared to the consensus revenue estimate of $1.9 billion.

What is Michael M. Morrissey's approval rating as Exelixis' CEO?

75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees. 38.0% of employees surveyed would recommend working at Exelixis to a friend.

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

Who are Exelixis' major shareholders?

Exelixis' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.81%), Meditor Group Ltd (0.73%), Assenagon Asset Management S.A. (0.60%), Allspring Global Investments Holdings LLC (0.42%), Amalgamated Bank (0.06%) and State of Alaska Department of Revenue (0.04%). Insiders that own company stock include Alan M Garber, Carl B Feldbaum, Christopher J Senner, Dana Aftab, David Edward Johnson, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends
.

How do I buy shares of Exelixis?

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EXEL) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners